Join

Compare · CGC vs MTCR

CGC vs MTCR

Side-by-side comparison of Canopy Growth Corporation (CGC) and Metacrine Inc. (MTCR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CGC and MTCR operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • CGC is the larger of the two at $2.86B, about 131.5x MTCR ($21.8M).
  • CGC has hit the wire 7 times in the past 4 weeks while MTCR has been quiet.
  • CGC has more recent analyst coverage (19 ratings vs 4 for MTCR).
MetricCGCMTCR
Company
Canopy Growth Corporation
Metacrine Inc.
Price
$1.01+1.00%
$0.49-0.50%
Market cap
$2.86B
$21.8M
1M return
-5.58%
-
1Y return
-30.00%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
7
0
Recent ratings
19
4
CGC

Canopy Growth Corporation

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

MTCR

Metacrine Inc.

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Latest CGC

Latest MTCR